Can You Use Nandrolone With Heart Disease? (TRT Q&As)
Timeline
A 59-year-old man on TRT asks about adding nandrolone or Anavar despite an ejection fraction around 49 and known coronary disease. Dr. O’Connor strongly advises against nandrolone in this setting, discusses its potential relationship with cardiomyopathy, and emphasizes protecting the heart and continuing appropriate cardiac treatment.
The 32-year-old member shares extensive labs while currently using HCG and clomiphene for fertility and asks about a future 16-to-20-week cycle. Dr. O’Connor declines to endorse a steroid cycle, emphasizing that the member is young and healthy and should protect that health reserve rather than assume good current labs make additional steroid exposure safe.
A 35-year-old man with low testosterone and SSRI treatment is concerned about testosterone, clomiphene, mood effects, and where to seek care. Dr. O’Connor emphasizes determining why testosterone is low, considering psychiatric history and fertility, and obtaining a thorough medical and endocrine evaluation before deciding whether to try testosterone.
A 25-year-old man describes testosterone falling after viral illnesses, feeling worse after starting TRT, and continuing to have low estradiol after stopping. Dr. O’Connor urges caution in such a young man, recommends allowing time for hormonal recovery, and stresses investigating the underlying endocrine and medical picture rather than automatically restarting testosterone.
The member reports resting and sleeping heart rates frequently in the 80s and 90s despite nebivolol, with his cardiologist considering a switch to metoprolol. Dr. O’Connor discusses evaluating possible causes such as thyroid issues, anemia, medications, cardiac function, and other medical factors rather than simply treating the heart-rate number in isolation.
A 44-year-old man who had a heart attack followed by stents and double bypass surgery asks whether testosterone could be reconsidered after several stable years. Dr. O’Connor reviews his cardiovascular risk factors and medications and explains that any decision about TRT requires careful risk assessment, aggressive cardiovascular management, appropriate monitoring, and coordination with his physicians.
Video Summary
This episode examines how ongoing monitoring shapes testosterone therapy decisions. It explains why symptoms and laboratory data must be interpreted together rather than independently. Hormone care is framed as longitudinal clinical management.
A central segment discusses common lab markers and how trends inform risk assessment and treatment adjustments. It emphasizes avoiding overreaction to isolated values. Balanced interpretation is presented as essential.
The closing portion reinforces testosterone therapy as structured, long-term care. Monitoring, education, and patient engagement are highlighted. The episode positions hormone management as a process guided by data and follow-up.
Drug Callouts
Condition Callouts
Key Takeaways
- Monitoring guides safe testosterone therapy decisions.
- Lab trends are more informative than isolated values.
- Symptoms must be interpreted alongside laboratory data.
- Overreaction increases the risk of unnecessary changes.
- Education and follow-up support long-term hormone care.